{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:38:26Z","timestamp":1794242306446,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["OPPK CZ.2.16\/3.1.00\/28007"],"award-info":[{"award-number":["OPPK CZ.2.16\/3.1.00\/28007"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["IGA NT\/13899"],"award-info":[{"award-number":["IGA NT\/13899"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007543","name":"Grantov\u00e1 Agentura, Univerzita Karlova","doi-asserted-by":"publisher","award":["GA UK\/177815"],"award-info":[{"award-number":["GA UK\/177815"]}],"id":[{"id":"10.13039\/100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13046-017-0523-3","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T09:23:29Z","timestamp":1492507409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment"],"prefix":"10.1186","volume":"36","author":[{"given":"Monika","family":"Jaruskova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Curik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajna","family":"Hercog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclava","family":"Polivkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliska","family":"Motlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Benes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Klamova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Pecherkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Belohlavkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Vrbacky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Machova Polakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,18]]},"reference":[{"key":"523_CR1","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"523_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208\u201315.","journal-title":"Blood"},{"key":"523_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"523_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003;4:75\u201385.","journal-title":"Lancet Oncol"},{"key":"523_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","volume":"3","author":"V Vasiliou","year":"2009","unstructured":"Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3:281\u201390.","journal-title":"Hum Genomics"},{"key":"523_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2141.1990.tb02533.x","volume":"74","author":"Y Kuwazuru","year":"1990","unstructured":"Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K, et al. Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis. Br J Haematol. 1990;74:24\u20139.","journal-title":"Br J Haematol"},{"key":"523_CR7","doi-asserted-by":"publisher","first-page":"e51771","DOI":"10.1371\/journal.pone.0051771","volume":"7","author":"O Singh","year":"2012","unstructured":"Singh O, Chan JY, Lin K, Heng CC, Chowbay B. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS One. 2012;7:e51771.","journal-title":"PLoS One"},{"key":"523_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1479-7364-3-2-195","volume":"3","author":"L He","year":"2009","unstructured":"He L, Vasiliou K, Nebert DW. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genomics. 2009;3:195\u2013206.","journal-title":"Hum Genomics"},{"key":"523_CR9","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064\u201372.","journal-title":"Blood"},{"key":"523_CR10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3892\/or.2012.2153","volume":"29","author":"M Gromicho","year":"2013","unstructured":"Gromicho M, Magalhaes M, Torres F, Dinis J, Fernandes AR, Rendeiro P, et al. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol Rep. 2013;29:741\u201350.","journal-title":"Oncol Rep"},{"key":"523_CR11","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15:4750\u20138.","journal-title":"Clin Cancer Res"},{"key":"523_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2012.066480","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 2013;98:193\u2013200.","journal-title":"Haematologica"},{"key":"523_CR13","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","volume":"112","author":"S Dulucq","year":"2008","unstructured":"Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008;112:2024\u20137.","journal-title":"Blood"},{"key":"523_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","volume":"28","author":"LN Ni","year":"2011","unstructured":"Ni LN, Li JY, Miao KR, Qiao C, Zhang SJ, Qiu HR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2011;28:265\u20139.","journal-title":"Med Oncol"},{"key":"523_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","volume":"35","author":"M Maffioli","year":"2011","unstructured":"Maffioli M, Camos M, Gaya A, Hernandez-Boluda JC, Alvarez-Larran A, Domingo A, et al. Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res. 2011;35:1014\u20139.","journal-title":"Leuk Res"},{"key":"523_CR16","doi-asserted-by":"publisher","first-page":"e6942","DOI":"10.1371\/journal.pone.0006942","volume":"4","author":"SE Hesselson","year":"2009","unstructured":"Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y, et al. Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS ONE. 2009;4:e6942.","journal-title":"PLoS ONE"},{"key":"523_CR17","doi-asserted-by":"crossref","unstructured":"Rozen S and Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa: Humana Press; 2000. p. 365\u2013386.","DOI":"10.1385\/1-59259-192-2:365"},{"key":"523_CR18","doi-asserted-by":"publisher","unstructured":"Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S and Madden T. Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012;13:134.","DOI":"10.1186\/1471-2105-13-134"},{"key":"523_CR19","unstructured":"OligoAnalyzer 3.1. https:\/\/eu.idtdna.com\/calc\/analyzer ."},{"key":"523_CR20","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","volume":"31","author":"MJ Machiela","year":"2015","unstructured":"Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555\u20137.","journal-title":"Bioinformatics"},{"key":"523_CR21","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC Muller","year":"2009","unstructured":"Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23:1957\u201363.","journal-title":"Leukemia"},{"key":"523_CR22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NC Cross","year":"2015","unstructured":"Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999\u20131003.","journal-title":"Leukemia"},{"key":"523_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124:511\u20138.","journal-title":"Blood"},{"key":"523_CR24","unstructured":"VassarStats: Website for Statistical Computation. http:\/\/vassarstats.net ."},{"key":"523_CR25","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1101\/gr.137323.112","volume":"22","author":"AP Boyle","year":"2012","unstructured":"Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790\u20137.","journal-title":"Genome Res"},{"key":"523_CR26","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A, O\u2019Brien S, Jabbour E, Romo CG, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013;121:4867\u201374.","journal-title":"Blood"},{"key":"523_CR27","doi-asserted-by":"publisher","first-page":"22811","DOI":"10.3390\/ijms160922811","volume":"16","author":"M Polillo","year":"2015","unstructured":"Polillo M, Galimberti S, Barate C, Petrini M, Danesi R, Di Paolo A. Pharmacogenetics of BCR\/ABL inhibitors in chronic myeloid leukemia. Int J Mol Sci. 2015;16:22811\u201329.","journal-title":"Int J Mol Sci"},{"key":"523_CR28","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1534\/genetics.106.064121","volume":"174","author":"AM Lee","year":"2006","unstructured":"Lee AM, Wu CT. Enhancer-promoter communication at the yellow gene of Drosophila melanogaster: diverse promoters participate in and regulate trans interactions. Genetics. 2006;174:1867\u201380.","journal-title":"Genetics"},{"key":"523_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1534\/genetics.109.106559","volume":"183","author":"SA Ou","year":"2009","unstructured":"Ou SA, Chang E, Lee S, So K, Wu CT, Morris JR. Effects of chromosomal rearrangements on transvection at the yellow gene of Drosophila melanogaster. Genetics. 2009;183:483\u201396.","journal-title":"Genetics"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T01:44:26Z","timestamp":1569030266000},"score":1,"resource":{"primary":{"URL":"http:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-017-0523-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,18]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1186\/s13046-017-0523-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,18]]},"article-number":"55"}}